Literature DB >> 12042248

Characterization of glucosylceramides in Pseudallescheria boydii and their involvement in fungal differentiation.

Marcia R Pinto1, Marcio L Rodrigues, Luiz R Travassos, Rosa M T Haido, Robin Wait, Eliana Barreto-Bergter.   

Abstract

Pseudallescheria boydii is a fungal pathogen that causes disease in immunocompromised patients. Ceramide monohexosides (CMHs) were purified from lipidic extracts of this fungus, showing that, as described for several other species, P. boydii synthesizes glucosylceramides as major neutral glycosphingolipids. CMHs from P. boydii were analyzed by high-performance thin-layer chromatography, gas chromatography coupled to mass spectrometry, fast atom bombardment-mass spectrometry, and nuclear magnetic resonance. These combination of techniques allowed the identification of CMHs from P. boydii as molecules containing a glucose residue attached to 9-methyl-4,8-sphingadienine in amidic linkage to 2-hydroxyoctadecanoic or 2-hydroxyhexadecanoic acids. Antibodies from a rabbit infected with P. boydii recognized CMHs from this fungus. Antibodies to CMH were purified from serum and used in indirect immunofluorescence, which revealed that CMHs are detectable on the surface of mycelial and pseudohyphal but not conidial forms of P. boydii, suggesting a differential expression of glucosylceramides according with morphological phase. We also investigated the influence of antibodies to CMH on growth and germ tube formation in P. boydii. Cultures that were supplemented with these antibodies failed to form mycelium, but the latter was not affected once formed. Similar experiments were performed to evaluate whether antibodies to CMH would influence germ tube formation in Candida albicans, a fungal pathogen that synthesizes glucosylceramide and uses differentiation as a virulence factor. Addition of antiglucosylceramide antibodies to cultures of C. albicans clearly inhibited the generation of germ tubes. These results indicated that fungal CMHs might be involved in the differentiation and, consequently, play a role on the infectivity of fungal cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12042248     DOI: 10.1093/glycob/12.4.251

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  29 in total

1.  Quality control of fungus-specific glucosylceramide in Cryptococcus neoformans by endoglycoceramidase-related protein 1 (EGCrP1).

Authors:  Yohei Ishibashi; Kazutaka Ikeda; Keishi Sakaguchi; Nozomu Okino; Ryo Taguchi; Makoto Ito
Journal:  J Biol Chem       Date:  2011-11-09       Impact factor: 5.157

2.  Structure, cellular distribution, antigenicity, and biological functions of Fonsecaea pedrosoi ceramide monohexosides.

Authors:  Leonardo Nimrichter; Mariana D Cerqueira; Eduardo A Leitão; Kildare Miranda; Ernesto S Nakayasu; Sandro R Almeida; Igor C Almeida; Celuta S Alviano; Eliana Barreto-Bergter; Marcio L Rodrigues
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 3.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

4.  Extracellular peptidase in the fungal pathogen Pseudallescheria boydii.

Authors:  Bianca Alcântara da Silva; André Luis Souza dos Santos; Eliana Barreto-Bergter; Marcia Ribeiro Pinto
Journal:  Curr Microbiol       Date:  2006-06-09       Impact factor: 2.188

5.  Dietary glucosylceramide enhances cornified envelope formation via transglutaminase expression and involucrin production.

Authors:  Tatsuya Hasegawa; Haruo Shimada; Taro Uchiyama; Osamu Ueda; Masaya Nakashima; Yasuhiro Matsuoka
Journal:  Lipids       Date:  2011-03-17       Impact factor: 1.880

6.  Detection of antibody against fungal glucosylceramide in immunocompromised patients: a potential new diagnostic approach for cryptococcosis.

Authors:  Asfia Qureshi; Dannah Wray; Ryan Rhome; William Barry; Maurizio Del Poeta
Journal:  Mycopathologia       Date:  2011-10-05       Impact factor: 2.574

7.  Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.

Authors:  Marcio L Rodrigues; Li Shi; Eliana Barreto-Bergter; Leonardo Nimrichter; Sandra E Farias; Elaine G Rodrigues; Luiz R Travassos; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  In vitro activity of the antifungal plant defensin RsAFP2 against Candida isolates and its in vivo efficacy in prophylactic murine models of candidiasis.

Authors:  Patricia M Tavares; Karin Thevissen; Bruno P A Cammue; Isabelle E J A François; Eliana Barreto-Bergter; Carlos P Taborda; Alexandre F Marques; Marcio L Rodrigues; Leonardo Nimrichter
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

Review 9.  Sphingolipids as targets for treatment of fungal infections.

Authors:  Rodrigo Rollin-Pinheiro; Ashutosh Singh; Eliana Barreto-Bergter; Maurizio Del Poeta
Journal:  Future Med Chem       Date:  2016-08-09       Impact factor: 3.808

10.  Sphingolipid biosynthetic pathway is crucial for growth, biofilm formation and membrane integrity of Scedosporium boydii.

Authors:  Rodrigo Rollin-Pinheiro; Victor Pereira Rochetti; Mariana Ingrid Dutra da Silva Xisto; Livia Cristina Liporagi-Lopes; Beatriz Bastos; Antonella Rella; Ashutosh Singh; Sonia Rozental; Maurizio Del Poeta; Eliana Barreto-Bergter
Journal:  Future Med Chem       Date:  2019-11-12       Impact factor: 3.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.